Intravenous Immunoglobulins (IVIG)

Subscribe to Selected New Research on Intravenous Immunoglobulins

2584 relevant articles (498 outcomes, 494 trials/studies) found for this Drug

Description: Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA.

Also Known As:

IVIG; Immunoglobulins, Intravenous; Alphaglobin; Endobulin; Gamimmune; Gamimmune N; Gamimune; Gamimune N; Gammagard; Gammonativ; Globulin-N; IV Immunoglobulins; Immune Globulin, Intravenous; Intraglobin; Intraglobin F; Intravenous IG; Iveegam; Modified Immune Globulin (Anti-Echovirus Antibody); Sandoglobulin; Venimmune; Venoglobulin; Venoglobulin-I; Globulin N; GlobulinN; Immunoglobulins, IV; Intravenous Immune Globulin; Venoglobulin I; VenoglobulinI; Antibodies, Intravenous; Intravenous Antibodies

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 58433

Globulins: 305

Serum Globulins: 74

Immunoglobulins: 20136

Antibodies: 77322

Intravenous Immunoglobulins: 2584

respiratory syncytial virus immune globulin intravenous: 19

HIV hyperimmune globulin: 17

Experts

1.	Shoenfeld, Y: 9 articles (07/2007 - 05/2000)
2.	Shoenfeld, Yehuda: 8 articles (07/2007 - 04/2002)
3.	Dalakas, Marinos C: 7 articles (02/2008 - 06/2003)
4.	Guillevin, L: 4 articles (01/2008 - 03/2000)
5.	Blank, Miri: 4 articles (07/2007 - 11/2002)
6.	Mouthon, L: 4 articles (12/2004 - 03/2000)
7.	Mouthon, Luc: 3 articles (01/2008 - 07/2003)
8.	Balthasar, Joseph P: 3 articles (06/2007 - 01/2004)
9.	Stangel, M: 3 articles (10/2005 - 01/2000)
10.	Toyka, Klaus V: 3 articles (04/2005 - 06/2002)

Related Diseases

1.	Infection 10/01/1998 - "Most studies demonstrate beneficial results of IVIG treatment, especially on frequency and severity of infections in patients with advanced HIV disease. " 01/01/2004 - "Treatment with IVIG (seven trials, n = 262) in cases of subsequently proven infection did result in a statistically significant reduction in mortality [typical RR 0.55 (95% CI; 0.31, 0.98)In spite of different geographical locations of the studies, differences in the mortality in the control groups (range 0% - 43.8%), the use of different IVIG preparations, and different dosing regimens, there was no statistically significant between-study heterogeneity for the outcome of mortality in the two analyses. " 01/01/2002 - "The intravenous immunoglobulins has been proven beneficial in prophylaxis and treatment of infections in patients with primary and secondary immunodeficiency. " 06/01/1987 - "IVIG (0.025 g/kg) administered topically by the intranasal route to anesthetized cotton rats at the height of RSV infection effected a 10(2.2)-fold reduction in viral titers of pulmonary tissues and a complete clearance of detectable virus in 92% of the animals within 24 h. " 01/01/1984 - "After receiving intravenous immune globulin, all three patients experienced complete remission of infection." Order ALL the reference details at left...
2.	Syndrome 08/15/2007 - "Similarly, trials failed to establish a role for IVIG in the treatment of secondary or primary progressive MS. Most consistent beneficial results with a reduction of relapse rates and a slowing of disability have been obtained in relapsing-remitting MS including clinically isolated syndromes although a most recent study did not confirm a reduction of disease activity based on clinical and MRI findings. " 05/01/1988 - "In other areas, such as in Kawasaki's syndrome, IVIG therapy have been shown to be highly beneficial in preventing long term disease sequelae by some investigators, but the field remains controversial. " 11/01/1995 - "For Guillain-Barré syndrome the efficacy of intravenous immune globulin has been proven in a randomized clinical trial. " 04/01/2005 - "In Guillain-Barré syndrome (GBS),IVIg and PE are similarly effective in accelerating the recovery but there is still little evidence that they can reduce mortality or long-term disability. " 10/01/2006 - "Despite normal distal conduction studies, a clinical diagnosis of Lewis-Sumner syndrome was made and the patient responded well to intravenous immunoglobulins. " Order ALL the reference details at left...
3.	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 08/01/1996 - "Of the 30 patients, 19 (63%) improved with IvIg treatments; nine out of 16 patients (56%) with chronic progressive CIDP, and 10 out of 14 patients (71%) with relapsing CIDP (differences were not statistically significant). " 06/01/1991 - "High-dose IVIG was a safe and effective adjunctive therapy for childhood CIDP in these four patients." 07/01/2008 - "On the basis of available data, IVIg can be recommended as a first-line treatment option for GBS and CIDP. " 12/09/2003 - "In a pilot study on 10 CIDP-DM patients with IV immunoglobulins and tight glycemic control, the CIDP-DM patients had a better outcome than DNP patients treated with tight glycemic control only." 06/01/2009 - "A recently published randomized placebo-controlled study of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) showed IVIG to be clinically effective also for this disorder in both short and long term. " Order ALL the reference details at left...
4.	Dermatomyositis (Dermatopolymyositis) 04/01/1992 - "In juvenile dermatomyositis, we report 2 uncontrolled trials of IVIG treatment that resulted in significant clinical improvement and steroid-sparing. " 11/01/1995 - "We describe a group of patients with dermatomyositis, resistant to available therapies, whose muscle strength, skin changes, and muscle biopsies improved significantly during treatment with intravenous immune globulin. " 12/30/1993 - "High-dose intravenous immune globulin is a safe and effective treatment for refractory dermatomyositis." 01/01/2000 - "IVIG is effective in selected dermatomyositis patients. " 05/01/1996 - "In a double-blind, placebo-controlled study, using objective criteria for improvement, IVIG demonstrated moderate to dramatic improvement in 75% of the patients with dermatomyositis. " Order ALL the reference details at left...
5.	Autoimmune Diseases (Autoimmune Disease) 06/01/2005 - "The efficacy of IVIG has been established only in several autoimmune diseases; clinical reports of trials, series, and case reports indicate significant improvement in many more autoimmune diseases. " 12/01/1993 - "Results from the present study suggest a novel mechanism by which IVIg may be beneficial in human autoimmune diseases." 11/01/1994 - "The effect was evaluated of intravenous gammaglobulin (IVIg), a successful therapy in various autoimmune diseases, in relapsing-remitting MS patients treated for three years. " 03/01/1990 - "These results support the concept that IVIg may be beneficial in selected autoimmune diseases by modulating the function of the idiotypic network." 01/08/1998 - "In conclusion, IVIg is a promising immunomodulary therapy that has been shown to be effective in some neurological autoimmune diseases. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Immunoglobulins (Immunoglobulin)
2.	Intravenous Immunoglobulins (IVIG)
3.	Immunoglobulin G (IgG)
4.	Adrenal Cortex Hormones (Corticosteroids)
5.	Antibodies
6.	Inosine Triphosphate (ITP)
7.	Autoantibodies
8.	Steroids
9.	Methylprednisolone
10.	Prednisone (Sone)

Related Therapies and Procedures

1.	Plasma Exchange
2.	Transplants (Transplant)
3.	Transplantation (Transplant Recipients)
4.	Aftercare (After-Treatment)
5.	Immunotherapy

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>